Genmab — Maj 2020

[mobbyduck1]

Genmab Announces Positive Topline Results in Phase III ANDROMEDA Study of Daratumumab in Light-chain (AL) Amyloidosis

[mobbyduck1]

https://ir.genmab.com/news-releases/news-release-details/genmab-announces-positive-topline-results-phase-iii-andromeda

[GeorgeBest]

Tak mobbyduck

[GeorgeBest]

hhmm - nul markedsreaktion

[E_L]

i think this calls for another quote from the Q&A "GeorgeBest Is there a change to see Andromeda presented at ASCO as a late breaker?
Jan Van de Winkel At this point we have not seen data from ANDROMEDA."

[SEACOP]

Hvor stort er markedet for Amyloidose ?

[SEACOP]

Sundhed.dk

(www.sundhed.dk)

[GeorgeBest]

Amyloidosis market US https://www.grandviewresearch.com/industry-analysis/amyloidosis-treatment-market

[GeorgeBest]

Tidligere har vi diskuteret 10 - 20% af MM markedet (størrelse). Men nok betydeligt mindre konkurrence i Amylodosis end i MM

[mobbyduck1]

der er ingen

[GeorgeBest]

Winkel siger: for which no approved treatments are available

[bikube]

Der står i mailen fra Genmab, at der er 3-4K nye tilfælde hvert år i U S.

[bikube]

S A siger kursen nu er 31,15, hvad er $ kurs.

[JørgenVarnæs]

673 vistnok

[mobbyduck1]

7,76

[mobbyduck1]

6,76

[JørgenVarnæs]

Tast usddkk i google

[bikube]

Nordea siger 6,7277 x 31,19 = 2098,4

[JørgenVarnæs]

Men det er da vist ath på us noteringen?

[bikube]

Absolut ja - tidligere var 31,02